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Abstract
Group A Rotavirus (RVA) is the leading cause of severe diarrhea in children. The aims of the present study were to determine
the neutralizing activity of VP6-specific llama-derived single domain nanoantibodies (VHH nanoAbs) against different RVA
strains in vitro and to evaluate the ability of G6P[1] VP6-specific llama-derived single domain nanoantibodies (VHH) to
protect against human rotavirus in gnotobiotic (Gn) piglets experimentally inoculated with virulent Wa G1P[8] rotavirus.
Supplementation of the daily milk diet with 3B2 VHH clone produced using a baculovirus vector expression system (final
ELISA antibody -Ab- titer of 4096; virus neutralization -VN- titer of 256) for 9 days conferred full protection against rotavirus
associated diarrhea and significantly reduced virus shedding. The administration of comparable levels of porcine IgG Abs
only protected 4 out of 6 of the animals from human RVA diarrhea but significantly reduced virus shedding. In contrast,
G6P[1]-VP6 rotavirus-specific IgY Abs purified from eggs of hyperimmunized hens failed to protect piglets against human
RVA-induced diarrhea or virus shedding when administering similar quantities of Abs. The oral administration of VHH
nanoAb neither interfered with the host’s isotype profiles of the Ab secreting cell responses to rotavirus, nor induced
detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration
of rotavirus VP6-VHH nanoAb is a broadly reactive and effective treatment against rotavirus-induced diarrhea in neonatal
pigs. Our findings highlight the potential value of a broad neutralizing VP6-specific VHH nanoAb as a treatment that can
complement or be used as an alternative to the current strain-specific RVA vaccines. Nanobodies could also be scaled-up to
develop pediatric medication or functional food like infant milk formulas that might help treat RVA diarrhea.
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Introduction
Diarrhea is the second most common cause of childhood
mortality worldwide, causing 1.3 million deaths among children
younger than 5 years of age [1]. Group A rotavirus (RVA) is the
leading cause of severe diarrhea in children worldwide and is
responsible for approximately 29% of all diarrheal deaths, causing
453,000 deaths per year [2–5]. Human rotaviruses (Group A, B
and C) have also been implicated as causative agents of diarrheal
outbreaks occurring in nursing homes [6], among travelers [7], in
day-care centers [8], and in patients suffering from a variety of
immunodeficiency conditions [9,10].
Rotaviruses have a genome consisting of 11 segments of double-
stranded RNA. Most segments encode a single polypeptide,
allowing the virus to express six structural proteins (VPs) and five
non-structural proteins (NSPs) [11]. Twenty-seven G-types and 35
P-types that independently elicit virus-neutralizing antibodies (Abs)
have been identified based on the RVA outer capsid proteins VP7
(G-type) and VP4 (P-type) [12]. Of these, G-types G1 to G4 and
G9 combined with P-types P[4], P[6] and P[8] account for most of
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the G-P combinations of human RVA detected globally. They are
responsible for approximately 90% of all RVA infections
worldwide, showing different relative proportions by year and
region [13–15]. Other genotypes such as G5, G8, G10 and G12 in
combination with P[7], P[8] and P[9] were recently reported
infecting children from South America, the Caribbean, Africa and
Asia with lower incidences [15–21].
Currently, diarrhea caused by RVA can be prevented through
vaccination but treatment strategies are non-specific, largely
symptom-based, and involve fluid, electrolyte replacement and
maintenance of nutrition [22]. Live-attenuated oral RVA vaccines
have variable degrees of efficacy and a high cost [23,24]. Recent
clinical trials showed that RVA vaccines have significantly lower
efficacy in countries with limited infrastructure and resources,
usually the countries with the highest RVA burdens [24]. Moreover,
vaccine-acquired human RVA infection and diarrhea has been
previously reported in children suffering from severe combined
immunodeficiency, which led the Centers for Disease Control to
issue a recommendation against their use in this population [25].
On the other hand, rotavirus-specific treatments such as passive
immunotherapy using antibodies (Abs) are associated with various
degrees of success against infectious diseases of different etiologies,
such as viral, bacterial, fungal and protozoal origin in both humans
and animals [10,22,26–35]. Therefore, we investigated llama-
derived single-chain antibody fragments (VHH) against rotavirus
VP6 protein as preventive therapy and a potential treatment option.
VHHs are the smallest molecules with antigen-binding capacity and
present distinctive properties that differentiate them from conven-
tional antibodies, such as the ability to remain intact in the
gastrointestinal tract during oral administration.
The RVA VP6 inner capsid protein is highly immunogenic and
constitutes the target antigen of most immunodiagnostic tests
[36,37]. Based on its nucleotide (nt) variability (85% nt identity
among VP6 of the same group), at least 17 VP6 I (for intermediate
capsid shell) genotypes have been described, I1 and I2 being the
most frequently found in human RVA strains [38,39]. Most
studies show that conventional Abs to VP6 lack extracellular
neutralizing activity in vitro [40–43]. Tosser et al. developed a
monoclonal Ab to VP6 (RV-133) that interacted with both double-
and triple-layer particles and induced partial decapsidation but
failed to neutralize RVA in vitro [40]. Burns et al. reported two IgA
monoclonal Abs to VP6 (clones 7D9 and 10C10) that did not
present detectable neutralizing activity in vitro but inhibited viral
transcription and completely protected against infection in vivo
[44,45]. However, conflicting results regarding the effectiveness of
VP6 Abs mediating passive protection in neonatal mice have been
reported [44,46]. Some studies showed that VP6-specific maternal
Abs did not provide passive protection against RVA-associated
diarrhea in neonatal mice [47,48] while others reported partial
protection in neonatal mice born to dams immunized with
recombinant VP6 derived from C486 RVA (G6P[1]I?) that did
not develop virus neutralizing Abs [41]. Similar studies that used
passive IgA monoclonal Abs to VP6 suggested that protection in
vivo is in fact mediated by the binding of VP6 IgA Ab to RVA,
which protects by intracellular neutralization during transcytosis in
the mouse gut [44,48–50]. In any case, it is well known that the
continuous presence of high titers of passive RVA Abs in the gut
lumen (naturally produced or artificially added to the milk) fully
protects against diarrhea and significantly reduces virus shedding
[43,51–53]. We have previously developed VHH against VP6
from bovine RVA strain C486 (G6P[1]I?). These VHH nanoAbs
neutralized RVA in vitro, independently of the serotype. This result
was further confirmed in vivo by partial protection of VHH clones
3B2 and 2KD1 against RVA challenge in a neonatal mouse
model, demonstrating for the first time the broad neutralization
activity of VP6 specific VHH nanoAbs in vitro and in vivo [54,55].
Neutralizing VHH nanoAbs directed to VP6 may provide a new
strategy for the prevention and treatment of RVA diarrhea.
However, being a heterologous source of Abs, the host immune
response to the passive treatment must be considered, especially in
view of plans to use llama VHH nanoAbs prophylactically and/or
therapeutically in humans. We chose for this study the Improved
Baculovirus Expression System (IBES technology), which uses
baculovirus expression vectors in combination with Trichoplusia ni
larvae as living biofactories. The benefits of this platform have been
largely proven for other recombinant proteins as a cost-efficient
production platform for a number of recombinant proteins [55–58].
The optimal production of high yields of fully functional VP6-specific
VHH derived from larvae has been published recently, wherein the
protective effect of this VHH nanoAb in mice was reported [55],
confirming previous results obtained with VHH derived from
Escherichia coli [54]. To test the VP6-specific VHH antibody against
human RVA gastroenteritis we chose the neonatal gnotobiotic (Gn)
pig model. The Gn piglets are a widely known animal model
susceptible to human RVA infection and disease and the pathoge-
nicity of RVA in Gn piglets mimics that after natural RVA infection
of infants. Furthermore their gastrointestinal physiology and mucosal
immune system resemble that of human infants [59–61].
Here, we assess the broad neutralizing activity of 3B2 VHH to
different genotypes of RVA circulating in humans; and evaluate
the passive protection conferred by oral administration of VP6-
specific VHH clone 3B2 against RVA-induced diarrhea in
neonatal Gn piglets experimentally inoculated with one of the
most prevalent strains of human RVA, Wa G1P[8]I1.
Results
VP6-specific VHH nanoAbs protect against human RVA
diarrhea and reduce virus shedding
The aim of the present experiment was to evaluate the
protection of orally administered G6P[1] VP6-specific VHH
Author Summary
Group A rotavirus (RVA) is the most common cause of
severe diarrhea in human infants worldwide. Live-attenu-
ated rotavirus vaccines are available to prevent rotavirus
diarrhea in children, although their efficacy in impoverished
areas has been questioned, in addition to not being suitable
for children suffering from immune deficiencies. Since no
rotavirus-specific treatments are available as an alternative,
we investigated llama-derived single-chain antibody frag-
ments (VHH) as preventive therapy and a potential
treatment option. Gnotobiotic piglets were chosen as an
animal model because their gastrointestinal physiology and
mucosal immune system resemble that of human infants.
We evaluated the broad neutralizing activity of a VHH clone
(3B2) to different genotypes of RVA circulating in humans,
and tested the efficacy of oral administration of 3B2 VHH as
a functional milk to prevent the diarrhea induced by one of
the most prevalent human RVA strains (G1P[8]). Supple-
mentation of the milk diet with 3B2 twice a day for 9 days
conferred full protection against rotavirus-associated diar-
rhea and significantly reduced virus shedding in gnotobiotic
piglets experimentally inoculated with a human RVA. This
study demonstrates the potential application of VHH to
prevent rotavirus-induced diarrhea, and suggests that VHHs
should be further investigated as a suitable treatment for
gastroenteritis.
VHH Antibodies Protect against Human Rotavirus
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against human RVA associated diarrhea in Gn piglets exper-
imentally inoculated with virulent Wa G1P[8]I1 RVA, one of the
most prevalent RVA strains circulating in human infants
worldwide [15–21]. The experimental design included five groups
of Gn pigs receiving milk supplemented with one of the following:
3B2 VHH nanoAbs (VHH produced against G6P[1]), Wa
G1P[8]I1 human RVA-specific porcine IgG Abs (IgG), G6P[1]
VP6-specific chicken IgY Abs (IgY), control larvae (CL) or Ab-free
milk (No Treatment, NT). The results for VN and ELISA isotype-
specific Ab titers to Wa human RVA in the supplemented milk are
depicted in Table 1. As shown, VP6-specific VHH nanoAbs had a
final Wa human RVA ELISA Ab titer of 4096 and a VN titer of
256 in the supplemented milk, similar to the Ab titers obtained in
porcine anti-Wa human RVA IgG supplemented milk used as a
positive homologous control treatment. Milk containing chicken
IgY polyclonal Abs purified from eggs of VP6-vaccinated hens
with a final Wa human RVA ELISA Ab titer of 4096 and a VN
titer to Wa human RVA of 64 was considered as a control for
heterologous conventional Abs to VP6. As expected, no Abs
against Wa human RVA were detected for CL supplemented milk
and Ab free milk -NT, consisting of sterile commercial bovine
milk- (Table 1).
Table 2 shows the presence of diarrhea and the amount of virus
shedding detected. Supplementation of the milk diet with VP6-
specific VHH nanoAbs for 9 days conferred full protection (5 of 5
animals protected) against Wa Human RVA diarrhea in Gn pigs.
The positive control group, pigs treated with the same ELISA and
VN titer of homologous IgG Abs to Wa human RVA, were
partially protected, as 4 out of 6 animals did not develop diarrhea
after virus inoculation. In the 2 piglets from this group that
developed diarrhea, there was a delay in the onset (post
inoculation day -PID-4; p = 0.0214) and a reduction in the mean
duration (0.7 days; p,0.0001) and in the mean cumulative
diarrhea score (4.0; p,0.0001), all of which differed significantly
compared to animals that did not receive any treatment (NT
group; no animals protected; mean onset: PID 2.2; mean duration:
6.8 days; mean cumulative diarrhea score: 15.6). Finally, animals
in the IgY and CL groups developed diarrhea with statistically
comparable protection parameters (in terms of percentage of
animals with diarrhea, mean onset, duration and mean cumulative
diarrhea score) to that of the NT group of pigs (Table 2).
Virus shedding was detected in all animals in the VHH group (5
out of 5 infected animals). Although the mean onset of virus
shedding was similar in all groups of pigs, in the VHH group, the
mean duration (3.0 days; p = 0.0012) and the AUC
(6.16104 FFU/ml*day; p = 0.0055) were significantly lower than
the ones in the NT group (mean duration: 5.6 days, AUC:
1.86106 FFU/ml*day). Mean peak titer and mean titer of virus
shed showed a trend toward lower values than in the NT group,
but not significantly so. For the IgG group, 5 of the 6 animals had
only a short duration and low amounts of virus shedding (mean
onset: PID 3.0; mean duration: 1.6 days; AUC: 1.96104 FFU/
ml*day). The mean peak titer (103.4 FFU/ml; p = 0.014) and mean
titer of virus shed (100.5 FFU/ml; p = 0.0012) for this group of pigs
were significantly lower than pigs in NT group (105.7 FFU/ml and
101.2 FFU7ml respectively). The IgY and CL groups were
intermediate between the positive control group (IgG group) and
the NT pigs regarding mean duration, AUC, mean peak titer and
mean titer of virus shed. There were no statistically significant
differences in the onset of virus shedding (IgY = CL = PID 1.8) and
the percentage of animals infected (IgY = CL = all the animals
infected) compared to the NT group (Table 2).
The profiles of individual infectious virus shedding as deter-
mined by CCIF assay are depicted in Figure 1. Pigs in the VHH
group showed a variable pattern of virus shedding, with some pigs
shedding RVA for only one day and other pigs shedding virus for
up to seven days. Only two pigs shed virus for one day after the
end of the treatment, but in low titers. No diarrhea was observed
in this group of pigs, indicative of asymptomatic virus shedding. In
the IgG group, five pigs shed virus for up to three days during the
administration of the treatment and there was no virus shedding
after the end of the treatment. Although all the pigs in the CL
group developed diarrhea and shed virus, one animal shed
infectious virus after the treatment ended, but without diarrhea.
The patterns of virus shedding in IgY, CL and NT groups were
similar, with high titers of RVA particles shed for several days
despite the administration of IgY or CL treatments (Figure 1 and
Table 2).
The oral administration of VHH nanoAbs did not affect
the host immune response to Wa human RVA after
experimental inoculation
The presence of porcine coproAbs to Wa human RVA was
evaluated daily in all the groups of pigs by isotype-specific ELISA
(Figure 2). The IgM Abs were first detected at variable time points
depending on the group of pigs and its presence was associated
with virus clearance (Figure 1). The IgM response was always
followed by IgA Ab responses. All the Ab titers detected were low
and this may be explained by the fact that samples were diluted
rectal swab fluids and not feces. In particular, IgA was the main
isotype detected in rectal swab fluids and intestinal contents.
We further evaluated the persistence of the VHH, IgY and IgG
Abs in rectal swab fluids after the treatments (Figure 2). The VHH
nanoAbs administered were detected in rectal swab fluids from
treated piglets by ELISA until up to two days after the end of the
milk supplementation (PID 9), but always in low titers. The VP6-
specific IgY Abs were also detected in rectal swab fluids, but only
at the beginning of the milk diet supplementation. Although the
supplemented Abs are indistinguishable from the host’s immune
response, no swine IgG Abs to RVA Wa were detected in rectal
swab fluids from the IgG group of pigs during the treatment
(Figure 2) suggesting that the treatment is being degraded in the
intestinal tract.
Table 1. VN and ELISA isotype-specific Ab titers to Wa HRV in
the supplemented bovine milk used to feed Gn piglets.
Group name Treatment group Ab titer to HRV Wa P[8]G1
ELISA VN a
VHH anti-VP6 VHH 4096 256
(VHH)
IgY anti-VP6 IgY 4096 64
(IgY)
CL control larvae ,4 ,4
(neg) (neg)
IgG anti-Wa HRV IgG 4096 256
(IgG)
NT Ab free milk ,4 ,4
(neg) (neg)
aDetermined by fluorescence focus forming unit reduction assay. A 10 ml (4.8
percent) aliquot of each Ab pool (VHH/IgY/Control larvae/IgG) was added to
210 ml of sterile commercial bovine milk to obtain the indicated final Ab titer to
Wa HRV. Neg =negative.
doi:10.1371/journal.ppat.1003334.t001
VHH Antibodies Protect against Human Rotavirus
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The porcine serum Ab isotype responses to Wa RVA are
depicted in Figure 3. At PID 7, IgM was the main Ab isotype
detected in pigs’ sera and titers coincided with the VN activity
detected. For all the experimental groups of pigs, except for the
IgG group, these results were also in agreement with the coproAb
responses previously described (Figure 2). Pigs in groups VHH,
IgY and CL showed statistically higher titers of IgM Abs in serum
at PID 7 (p = 0.0015) and PID 14 (p = 0.0033) than the IgG group;
the NT group had intermediate titers at this experimental time
point (PID 7). No other significant differences in porcine Ab titers
to Wa RVA were detected in sera. There was a progressive
increase in VN Ab titers over time during the experiment in
animals from all groups, with the highest titers detected at PID 21,
together with the presence of IgA and IgG Abs to Wa RVA
(Figure 3).
No heterologous Abs derived from the treatments (Abs to VHH
and IgY) were detected in serum samples from treated piglets at
PID 0, 7, 14 and 21 by ELISA (data not shown).
Ab Secreting Cell responses to Wa RVA infection were
detected in all the tissues studied from all the
experimental groups at PID 21
The Ab Secreting Cell (ASC) responses to RVA in systemic
lymphoid tissues and gastrointestinal lymphoid tissues (GALT) at
PID 21 were evaluated by ELISPOT assay and (Figures 4 and 5,
respectively). Results for IgM ASCs in tissues at PID 21 are not
shown since few of them were detected. There were statistically
higher IgG ASC numbers in blood from the VHH group
compared with the IgG group, while the CL, IgY and NT groups
showed intermediate numbers (p = 0.003) (Figure 4). The numbers
of IgA ASC were significantly higher in mesenteric lymph nodes
(MLN) from the NT group than in the groups receiving human
RVA-specific Abs as treatments (VHH, IgY and IgG groups)
(p = 0.026). No further significant differences were observed in
ASC numbers in systemic lymphoid tissues and MLN between
groups (Figure 4).
Different numbers of ASC to Wa RVA at PID 21 in the GALT
were detected in all the intestinal tissues studied (Figure 5). At PID
21, IgA was the main ASC isotype detected in the GALT from all
groups of pigs, followed by IgG. The ASC numbers were
statistically similar among groups. However, the IgA ASC
numbers from jejunum were significantly lower in the VHH
group compared with all other groups of pigs (p = 0.019). A trend
towards lower numbers of ASC was observed in the VHH group
compared with the NT group, but no other significant differences
were detected (Figure 5).
Nanobodies-specific immune responses were not
detected in VHH treated piglets during the study period
The presence of a nanobody-specific immune response in VHH
and IgY treated animals was determined by ELISA in sera and
intestinal contents of treated piglets (Figure 6). The IgG Ab levels
were determined in serum samples weekly. In the intestinal
contents, IgA Ab responses were determined together with IgG
Abs to VHH nanoAbs at PID 21. In spite of the presence of low
titers of orally administered VHH nanoAbs in rectal swab fluids
from the VHH group, the treated piglets did not develop specific
Ab responses to the VHH nanoAbs neither in serum nor in the
intestinal contents by PID 21 (Figure 6). Further analysis of rectal
swab fluids also failed to detect porcine Abs to the VHH nanoAb
(data not shown).
In contrast, piglets fed with milk supplemented with IgY Abs to
VP6 developed a humoral Ab response to the IgY Ab, (Figure 6).
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Figure 1. Mean titer of virus shed per day per pig (from CCIF assay) detected daily in rectal swab fluids of the experimental groups
of piglets. All animals were orally inoculated at 72 h of age [0 post inoculation day (0 PID)], and euthanized at 2163 PID. SIC: small intestinal
contents; and LIC: large intestinal contents, were collected after euthanasia. Horizontal bars represent the mean days of diarrhea duration for each
group. The arrow at 0 PID indicates the inoculation day. The thin line indicates the duration of the passive treatments.
doi:10.1371/journal.ppat.1003334.g001
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Figure 2. Geometric mean isotype-specific Ab titers (GMT) to Wa HRV per group per day (from ELISA assay) detected in rectal swab
fluids of the experimental groups of piglets. All animals were orally inoculated at 72 h of age [0 post inoculation day (0 PID)], and euthanized at
2163 PID. SIC: small intestinal contents; and LIC: large intestinal contents, were collected after euthanasia. The arrow at 0 PID indicates the inoculation day.
doi:10.1371/journal.ppat.1003334.g002
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Piglets in the IgY group developed serum IgG Abs to IgY at PID 7
(9 days after starting the treatment), with a peak at PID 14. The
IgA and IgG Abs to chicken IgY were also observed in the
intestinal contents at PID 21 (Figure 6), but not in rectal swab
fluids (data not shown).
As expected for the piglets that did not receive heterologous
immunoglobulins, no IgG/IgA Abs to IgY or VHH were detected
in CL, IgG and NT piglets in serum, rectal swab fluids or intestinal
contents (Figure 6 and data not shown). Swine Abs to porcine IgG
were not tested, as an immune response of the host to homologous
Abs is not expected.
VHH 3B2 showed broad neutralization activity against
several RVA genotypes in vitro
To further characterize the ability of VHH nanoAbs to
neutralize RVA, a virus neutralization assay was performed using
several RVA strains. The RVA strains were selected considering
their G-, P- and I-genotypes in order to include as many genotypes
circulating in humans as possible (Table 3).
VHH nanoAb 3B2 was able to neutralize all the RVA strains
tested at different concentrations, ranging from 15.63 mg VHH/
ml for SA11 strain to 0.06 mg VHH/ml for Wa and F45 strains. As
a control, non-related VHH nanoAb was not reactive against any
of the RVA strains tested (Table 3).
Discussion
The VP6 constitutes the inner capsid of rotavirus and it is the
most abundant and immunodominant viral protein. The Abs
directed to VP6 are highly cross-reactive among RVA so VP6
immunization could potentially provide heterotypic protection
[62]. The main objective of the present study was to determine the
efficacy of the oral administration of G6P[1] VP6-specific VHH
nanoAbs against Wa G1P[8]I1 human RVA-induced diarrhea in
a Gn pig model of infection and disease. The 3B2 VHH clone
protected all treated animals from RVA-induced diarrhea when
administered daily as milk supplement at a final Wa RVA ELISA
Ab titer of 4096 (VN titer of 256) during nine consecutive days.
The protection observed was comparable to that in pigs treated
with porcine IgG Abs to Wa RVA at the same ELISA and VN
titers. This latter group of pigs was considered the positive control
group, simulating the protection conferred by homologous Abs
[63,64]. The presence of diarrhea in 2 out of 4 animals from the
IgG group suggests that this passive treatment with homologous
Abs is not completely capable of preventing RVA-induced
diarrhea against the challenge dose administered. However, the
homologous treatment still conferred a great degree of protection,
highlighting the importance of passive maternal Abs in newborns.
These results reinforce the importance of the use of RVA vaccines
(to induce active immunity) but also state the precedent that
additional RVA-specific strategies might be useful to control and
prevent RVA diarrhea in human infants.
Passive or active protection against RVA diarrhea is the most
desirable outcome of any treatment or vaccination and can be
achieved even when continued viral shedding is detected in stools.
Moreover, the asymptomatic infection allows development of
active immunity (as noted in our study) to prevent subsequent
natural RVA infections. In our study, passive treatment with
homologous porcine IgG Abs also provided a high degree of
protection against virus shedding. However, the production of
large amounts of polyclonal human IgG Abs specific to RVA
needed for children would be difficult to implement and Abs
would be mostly RVA strain-specific. We investigated a more
universal treatment against a wide range of RVA strains applicable
for neonatal humans or animals, based on VHH technology,
which is easy to scale up and presents distinctive advantageous
properties over traditional antibodies.
The 3B2 VHH clone expressed in E. coli was previously
characterized and showed a broad neutralizing activity against
RVA in vitro, independently of the RVA serotype [54]. Remark-
ably, this VHH was developed against the VP6 of bovine C486
(G6P[1]I?) RVA strain, but it showed broad neutralization activity
in vitro against RVA of heterologous serotypes and species of origin
including Wa HRV [54]. Furthermore, this result was confirmed
by in vivo partial passive protection against bovine RVA strain
C486 and murine RVA strain ECW (G16P[16]I7) at 48 h post
challenge in a neonatal mouse model using 1 mg/ml (22,2 mg/
kg/day) of recombinant VHH administered once a day for 5
consecutive days [54]. The 3B2 VHH clone expressed in insect
cell cultures had the same therapeutic properties as the one
expressed in E. coli in the neonatal mouse model [55]. In the
present study, 3B2 VHH neutralized virus infection in vitro from
several RVA strains and this seemed to be independent of the G-,
P- and I-genotypes of RVA strains tested. The results obtained in
vitro demonstrate that the 3B2 VHH nanoAb inhibits infection by
relevant RVA strains circulating in humans worldwide, including
not only Wa (G1P[8]I1), but also DS1 (G2P[4]I2), 69M
(G8P[10]I2), F45 (G9P[8]I?) and Arg720 (G12P[9]I?) among
others (Table 3). In addition, a high in vivo protection rate was
observed in this study against VirWa human RVA inoculation in
Gn pigs fed with 22 mg of VHH nanoAbs per 210 ml of milk
(0.1 mg/ml of milk, 44 mg/pig/day or 20–40 mg/kg/day).
VHH nanoAbs protected against RVA-induced diarrhea in all
the animals tested, even when all the animals shed virus infective
particles. Since VHHs are recombinant monoclonal Abs, the
possibility of VP6 escape mutant selection should be considered.
Further studies are underway to determine if VHH nanoAbs
promote VP6 escape mutants in vitro and in vivo. This information
will help us better understand how the VHH nanoAbs inhibit
RVA infection.
Chicken egg yolk IgY Abs to G6P[1] VP6 were also used as a
control for treatment with heterologous conventional Abs. This
treatment was not protective against RVA diarrhea or virus
shedding in Gn pigs. These results obtained in gn pigs, an animal
model that closely resembles RVA pathogenicity in human infants,
are in agreement with the lack of protection observed in a mice
model using other conventional Abs directed to VP6 protein
[47,48]. Of note, the avian IgY Abs were obtained from VP6-
vaccinated hens with pre-existing VN activity to Wa RVA. Avian
rotavirus is endemic in hens [11] and it has been reported that
mammalian and avian RVAs have a low degree of nucleotide
sequence identity for all eleven genome segments [39,65]. This
may explain the presence of only low pre-existing VN activity to
RVA in the chickens due to cross reactivity.
Serum, coproAbs, and ASC responses were tested to assess the
development of the pigs’ immune responses to Wa RVA. The
highest ASC responses to Wa RVA were in the GALT at PID 21,
with lower ASC numbers in systemic lymphoid tissues. Our results
indicate that pigs receiving passive Ab treatments (IgG, IgY or
VHH) had the same isotype profile of IgA ASC but of lower
Figure 3. Wa HRV-specific porcine Abs in piglet’s sera. The isotype-specific and VN Abs to Wa HRV in serum samples were determined weekly
by ELISA and VN assay. The arrow indicates the experimental inoculation with Wa HRV (0 PID). PID: post inoculation days.
doi:10.1371/journal.ppat.1003334.g003
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magnitude than piglets in NT group, suggesting some interference
effect. A short delay in the development of the immune response
and a lower number of ASC were also evident in the group of pigs
treated with VHH (in particular, reduced IgA ASC in jejunum).
However, the magnitude of the Ab responses developed was
potent enough to prevent Wa RVA diarrhea after a second
exposure to the virus, in agreement with previous reports [66].
However, it is unclear if the passive treatment with VHH nanoAbs
affected the development of the pigs’ immune response to RVA
infection. The absence of diarrhea, and thus a lower level of viral
replication, probably affects the development of a stronger
immune response.
The administration of control larvae as passive treatment (CL)
failed to prevent RVA-associated diarrhea and did not signifi-
cantly modify piglets’ immune responses to Wa human RVA, but
showed a trend toward less severe diarrhea, virus shedding and
lower number of ASC compared to the NT group. An explanation
for this phenomenon is not clear and may be related to biological
factors in the harvested T. ni larvae that may have an adjuvant or
immunopotentiating effect on innate immunity in the Gn pigs. It
has been described that baculovirus could elicit antiviral activity in
mammalian cells, both in vitro and in vivo, but this hypotheses
should be further explored [67]. However, the control larvae
group trend to reduce virus shedding was not enough to
statistically modify the diarrhea-associated parameters, as it was
not significantly different from NT control group.
A critical point to be considered is the host’s immune response
to the passive treatment with heterologous Abs, as it has serious
health implications such as the development of allergy and other
hypersensitivity reactions. In this study, a heterologous neutraliz-
ing VHH nanoAb was examined as a prevention strategy against
human RVA in an animal model that closely mimics the intestinal
physiology of human infants. VHH-treated piglets did not develop
detectable humoral Ab responses against the passive VHH
treatment (in serum, rectal swab fluids, or intestinal contents) by
the methodology used. In contrast, piglets treated with IgY Abs to
VP6 developed a humoral Ab response to the passive IgY
treatment, characterized by the presence of IgG Abs to IgY in
serum and both IgG and IgA Abs to IgY in the intestinal contents.
Equally important, no heterologous Abs derived from the VHH or
IgY passive treatment were detected in sera of treated animals,
which suggests that there was no transmission of VHH or IgY Abs
from the gut lumen to the blood. It is well documented that under
physiological, non-inflamed conditions, dendritic cells migrate
from mucosa to present antigens in the lymph nodes [68]. As a
result, dietary antigens are presented in association with signals
that drive a suppressive immune response. It has been reported
that IgY is highly immunogenic as it has been used as a model
antigen for testing mucosal adjuvants, which might explain the
presence of IgG anti IgY in sera of treated animals [69,70]. On the
contrary, the oral administration of VHH nanoAbs might induce a
tolerant state, preventing the host from eliciting an anti-VHH
immune response, but further studies must be conducted to
confirm this statement.
It has been previously reported that passive VHH nanoAbs to
VP6 with similar VN activity were protective against RVA in vivo
in mice [71–75]. Briefly, Van der Vaart et al. produced VHH
nanoAbs to a G3 Rhesus-monkey RV (RRV) strain in yeast. Daily
oral administration of 50–100 mg/pup (20–40 mg/kg/day) during
five days reduced the morbidity of RRV-induced diarrhea in mice,
but it was unclear whether the VHH nanoAbs were effective
against other rotavirus strains [73]. Pant et al. also produced VHH
nanoAbs to G3 RRV in Lactobacillus paracasei, in both secreted and
cell surface–anchored forms. Lactobacilli expressing membrane
anchored nanoAbs showed neutralizing activity in vitro. The
prophylactic use of those VHH nanoAb during 5 days reduced the
frequency, duration and severity of diarrhea in mouse pups after
oral inoculation with RRV [72,75]. Recently, Aladin et al. further
characterized the same VHH clones (ARP1 and ARP3) and
reported in vitro neutralizing activity against several RVA strains
including human RVA strains Wa, DS1, 69M, F45 and ST3, but
failed to neutralize SA11 and one of the RRV strains tested.
Although these VHH nanoAbs were developed against complete
RRV, ARP1 and ARP3 are also directed to VP6 as evidenced by
western blot analysis. [71] In contrast, ARP1 and ARP3 recognize
a lineal epitope of VP6 unlike 3B2 VHH that is directed to a
conformational epitope [54,71]. Collectively, the evidence ob-
tained from Aladin et al. together with our results suggest that the
ability of VHH nanoAbs to inhibit in vitro virus replication does not
correlate with a specific VP6 genotype as several RVA strains with
different G-, P- and I-genotypes were neutralized by VHHs.
However, 3B2 VHH appears to be much more efficient in
inhibiting strain-specific RVA replication than ARP1 and ARP2
VHHs [71], as lower amounts of 3B2 VHH were needed to
neutralize Wa, DS1, ST3, F45 and 69M RVA infection in vitro.
This assumption should be confirmed testing the VHH nanoAbs
(3B2, ARP1 and ARP3) under the same conditions.
The VHH nanoAbs were the first Abs to demonstrate
extracellular neutralizing activity. The mechanism by which
VHH nanoAbs inhibit virus replication is still unclear and several
studies are in progress in our laboratory to elucidate it. With this in
mind, Feng et al. showed that the attachment of a VP6-specific IgA
monoclonal Ab to VP6 introduced a conformational change in the
VP6 trimer, rendering the particle transcriptionally incompetent
and preventing the elongation of initiated transcripts [45]. Since
monoclonal Abs to VP6 are capable of inhibiting RVA
transcription [76], it reinforces the idea that VP6 IgA Abs confer
protection in vivo by inhibiting viral transcription at the start of the
intracellular phase of the viral replication cycle. It is widely known
that the VP6 protein plays a key role in the organization of the
virion, because it is in direct contact with the inner and the outer
protein shells. Likewise, VP6 is the physical adaptor between two
biological functions critical for RVA: cell entry (related to the virus
outer layer) and genomic RNA packaging (related to the inner
layer) [11,77]. Although the VP6 protein is only exposed in
double-layered particles, VHH nanoAbs of smaller size than
conventional Abs, could penetrate the outer shell, bind VP6, and
block decapsidation, inhibiting the early steps of virus replication.
An improved structural understanding of the common features of
the different RVA strains neutralized by VHH nanoAbs will shed
light into this mechanism.
Finally, our results indicate that the VHH clone 3B2 is a
recombinant monoclonal nanoAb that should be further explored
as a potential treatment of RVA-associated diarrhea, as it showed
100% efficacy against Wa G1P[8]I1 RVA-induced diarrhea in vivo,
and a broad neutralizing activity against several RVA strains
Figure 4. Numbers of Wa HRV-specific ASC per 56105 MNC obtained from systemic lymphoid tissues (blood and spleen) and MLN
draining the small and large intestine at 21 PID.When comparing ASC numbers of the same isotype among treatment groups, different letters
indicate a significant difference (Kruskal-Wallis rank sum test, p,0.05). n = number of piglets in each group. The IgM ASC response was not included
as no IgM ASC were detected in most of the groups of pigs.
doi:10.1371/journal.ppat.1003334.g004
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Figure 5. Numbers of Wa HRV-specific ASC per 56105 MNC obtained from gut-associated lymphoid tissues (Duodenum, Jejunum,
Ileum) 21 PID. When comparing ASC numbers of the same isotype among treatment groups, different letters indicate a significant difference
(Kruskal-Wallis rank sum test, p,0.05). n = number of piglets in each group. The IgM ASC response was not included as no IgM ASC were detected in
most of the groups of pigs.
doi:10.1371/journal.ppat.1003334.g005
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circulating in humans worldwide in vitro [54]. This VHH nanoAb
would also have the advantage of producing and administering a
single antibody in contrast to a cocktail of different conventional
Abs directed to the common G-P RVA strains circulating in
human populations. Additionally, it could be scaled-up to develop
pediatric medications or functional foods like infant milk formulas
to control RVA diarrhea. Producing VHHs using an expression
system with high production efficiency or downstream processing
is crucial, since the commercial application of this treatment will
greatly depend on the VHH nanoAb production costs. Additional
studies will be needed to determine the safety and efficacy of
VHHs against different RVA wild type strains as well as the
stability and administration regime of a treatment. In summary,
our findings show the potential value of broad neutralizing VP6-
specific VHH nanoAbs as a treatment that could complement (but
not replace) the use of serotype-specific RVA vaccines. This study
represents a proof of principle of the efficacy of VHH oral therapy
to prevent RVA diarrhea. This type of treatment has great
potential to be implemented in developing countries, where RVA
mortality is high and current vaccines seem less efficacious, and
also to be administered to prematurely born or immunodeficient
children worldwide [25,78].
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations by the Public Health Service Policy, United
States Department of Agriculture Regulations, the National
Research Council’s Guide for the Care and Use of Laboratory
Animals, and the Federation of Animal Science Societies’ Guide
for the Care and Use of Agricultural Animals in Agricultural
Research and Teaching, and all relevant institutional, state, and
federal regulations and policies regarding animal care and use at
The Ohio State University. The study protocol was approved by
the Committee on the Ethics of Animal Experiments of The Ohio
State University (Protocol Number: 2010A00000088). All the pigs
were maintained, samples collected, and then euthanized, and all
efforts were made to minimize the suffering of animals.
Oral inoculation of neonatal pigs with Wa RVA caused
transient diarrhea of variable severity from which piglets recovered
spontaneously within a few days. The euthanasia was performed
by electrocution following anesthesia. For this particular study, we
used the lowest number of pigs previously shown to permit
detection of statistical significances among treatments considering
welfare principles. A statistician verified the minimum number of
pigs required per treatment group before starting the experiments.
Preparation of Ab pools
VP6-specific recombinant VHH nanoAbs. The recombi-
nant baculovirus expressing 3B2 or a non-related VHH clone was
constructed as previously described [55]. We incorporated a His-
tag sequence at Carboxy-terminus of the protein to facilitate the
VHH purification. The T. ni larvae were intraemocelically injected
with 5 ml of recombinant baculovirus inoculum containing 56104
plaque forming units (PFU) and were kept in growth chambers at
28uC in specifically designed rearing insect modules. Infected
larvae were collected after 72 h post infection (hpi) and
immediately frozen at 270uC. A comparable weight of mock-
infected control larvae was equally processed. Larvae were
lyophilized overnight in a Telstar Cryodos freeze-dryer (Telstar,
Madrid, Spain), and stored at 4uC until used. Lyophilized insect
material (18 g of freeze-dried insect larvae containing about
400 mg of VHH and the same amount of control larvae) was
crushed in sterile plastic bags by a blender to obtain a powder,
which was kept at 4uC until use. To recover the recombinant
VHH, the larvae powder contained in BagFilter S bags
(Interscience, Saint Nom, France) was reconstituted in 360 ml
per batch of sterile phosphate-buffered saline (PBS), pH 7.4 as
extraction buffer. The resulting suspension was filtered through
the bag filter paper (porosity of the filter,250 microns), recovered
and centrifuged at 10,0006g for 15 min, and the pellet was
discarded. The supernatants were sterilized by filtration (0.22-mm-
pore-size membrane filter; Millipore, Billerica, USA), divided in
10 ml aliquots and stored at 220uC until used. The 3B2 VHH
nanoAbs recovered from the larvae powder batch had an ELISA
Ab titer against Wa RVA of 1,048,576 and virus neutralization
(VN) titer of 65,536. The preparation from mock-infected larvae
tested negative in both assays (,4). The 10 ml aliquots of the
corresponding preparation were used to supplement 210 ml of Ab
free commercial bovine milk. For the 3B2 VHH supplemented
milk (VHH group of pigs), each 10 ml aliquot contained 22 mg of
VHH nanoAbs and had a Wa RVA ELISA Ab titer of 4096 and a
VN titer of 256. The milk supplemented with mock infected larvae
Figure 6. Immune responses to the passive treatments were determined in sera and intestinal contents of treated piglets.
Continuous lines represent geometric mean of porcine IgG Ab titers (GMT) to the corresponding treatment administered (VHH, IgY or IgG Abs) in
serum samples per group every 7 days. Dashed lines represent ELISA Ab titer of passive Abs to Wa HRV (VHH, IgY or IgG Abs) in rectal swabs every 7
days. The bars at PID 21 represent porcine IgG and IgA Abs to passive treatment in SIC: small intestinal contents and LIC: large intestinal contents
collected after euthanasia. All animals were orally inoculated at 72 h of age [0 post inoculation day (0 PID)], and euthanized at PID 2163. The arrow at
PID 0 indicates the inoculation day. Different letters indicate significant differences between groups (p,0.05). In the case of groups CL, IgG and NT
the results represent porcine IgG Ab titers to chicken IgY in serum but a similar response was observed against VHH nanoAbs (data not shown).
doi:10.1371/journal.ppat.1003334.g006
Table 3. In vitro RVA fluorescent focus reduction assay using
VHH antibodies.
RVA strain Neutralizing VHH concentration (mg VHH/ml)
3B2 VHH clone Non-related VHH clone
Wa (G1 P[8] I1) 0.06 Neg
DS1 (G2 P[4] I2) 0.24 Neg
SA11 (G3 P[1] I2 ) 15.63 Neg
Gottfried (G4 P[6] I1) 0.24 Neg
ST3 (G4 P[6] I1) 0.98 Neg
H1 (G5 P[7] I5 ) 0.98 Neg
69M (G8 P[10] I2) 0.98 Neg
F45 (G9 P[8] I?) 0.06 Neg
Arg720 (G12 P[9] I?) 3.91 Neg
A fourfold dilution of each VHH clone (3B2 VHH, derived from llamas vaccinated
with VP6 from RVA strain C486 -G6P[1]I?-,or non-related VHH nanoAb) was
mixed with an equal volume of RVA containing 100 focus forming units (FFU) of
each strain. The numbers represent the minimum VHH concentration that
reduced .80% of the number of fluorescent focus forming units (FFU) of each
RVA strain. Neg= no neutralizing activity was observed at the highest
concentration tested (62.50 mg VHH/ml). The G-type, P-type and I-type of RVA
strains is clarified in brackets next to each strain name (according to [91]).
doi:10.1371/journal.ppat.1003334.t003
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(Control Larvae –CL- group of pigs), had a Wa RVA ELISA Ab
titer of ,4 and a VN titer of ,4, as detailed in Table 1.
VP6-specific IgY Abs from egg yolk. The egg yolk pools
used in this study were obtained from immunized hens. Eight-
week old Lohmann Brown Classic laying hens were housed in
cages specially designed for this purpose in groups of two animals
per cage following animal welfare recommendations [79,80].
Room temperature, relative humidity and light/dark cycles were
controlled. Hens were fed laying hen diet and provided water ad
libitum, and eggs were collected daily starting at the first
immunization. To generate VP6-specific IgY Abs from egg yolk,
ten hens were hyperimmunized with recombinant VP6 from RVA
as previously described [53]. Serum samples and egg yolks were
collected, and IgY Ab titer to Wa RVA was determined by ELISA.
Pools of egg yolks from the immunized hens were prepared weekly
and were diluted in distilled water at a ratio of 1:3, and freeze-
thawed to separate the emulsion. The Abs were precipitated
following an ammonium sulphate precipitation protocol as
previously described [53]. The pellet obtained was resuspended
in PBS pH 7.4 at a 1:10 ratio of the original volume of the egg yolk
pool and dialyzed against the same buffer, sterilized by filtration
(0.22-mm-pore-size membrane filter; Millipore), divided in 10 ml
aliquots and stored at 220uC until used. The final volumes
recovered were slightly different from the initial ones after dialysis.
The IgY Ab titer to Wa RVA was determined by ELISA and VN
assays. The 210 ml of sterile bovine milk supplemented with 10 ml
of IgY preparation (IgY group of pigs) had a final ELISA IgY Ab
titer to Wa RVA of 4096 and a VN titer of 64 (Table 1).
Wa RVA IgG Abs from immune sow serum. RVA-
seropositive sows (n = 2) received five doses of attenuated Wa
RVA (,107 FFU/dose) intramuscularly at 2-week intervals, with
the first dose in Freund Complete Adjuvant (FCA), followed by
three doses in Freund Incomplete Adjuvant (FIA) and the last one
without any adjuvant. A week after the last immunization, serum
was collected and pooled as previously described [53]. The Abs
were precipitated following the same ammonium sulphate
protocol used for IgY Abs and then filtered (0.22-mm-pore-size
membrane filter; Millipore), divided in 10 ml aliquots and stored
at 220uC until used. Purified IgG Abs from sow serum served as
the source of positive homologous IgG Abs to Wa RVA. Each
210 ml portion of milk supplemented with 10 ml of IgG
preparation (IgG group of pigs) had a final ELISA IgG Ab titer
to Wa RVA of 4096 and a VN titer of 256 (Table 1).
Virus
The intestinal contents of RVA Wa G1, P1A [8] infected Gn
pigs were diluted in minimal essential medium (MEM; Invitrogen,
Carlsbad, USA), and used for virus inoculation as described [64].
Attenuated Wa HRV (cell culture adapted) was propagated in
monkey kidney (MA-104) cells for use in sow hyperimmunization,
enzyme-linked immunospot assay (ELISPOT), ELISA and VN
assays. The RVA strains DS1 (G2P[4]I2), SA11 (G3P[1]I2),
Gottfried (G4P[6]I1), ST3 (G4P[6]I1), H1 (G5P[7]I5), 69M
(G8P[10]I2), F45 (G9P[8]I?) and Arg720 (G12P[9]I?) were
propagated in monkey kidney (MA-104) cells for use in VN assays.
Continuous cell lines
The MA-104 cell line of fetal rhesus monkey kidney cells
(passage 36) was originally purchased from Microbiological
Associates (now BioWhittaker, Radnor, USA). The Sf9 cell line,
a clonal isolate derived from Spodoptera frugiperda (Fall Armyworm),
was obtained from Invitrogen and cultured in Grace’s insect media
(GIBCO, Carlsbad, USA) supplemented with 10% fetal bovine
serum (FBS, GIBCO), 3% non-essential amino acids (Invitrogen),
1% nystatin, streptomycin and penicillin and 20 mg/ml gentamy-
cin (Invitrogen). Sf9 cells were grown at 27uC and MA-104 cells at
37uC in a 5% CO2 –air atmosphere.
Gnotobiotic pigs: Experimental design, virus inoculation,
clinical observations and sample collection
Gnotobiotic pigs. the Gn pigs were derived by hysterectomy
of near-term sows and maintained in isolator units as previously
described [81,82]. Pigs were allocated to one of five groups as
detailed in Table 1. The ELISA Ab titer to Wa RVA was used as
the adjusting parameter to compare the three different Ab passive
treatments used: monoclonal VP6-specific llama-derived 3B2
VHH nanoAbs; VP6-specific chicken egg yolk IgY Abs; and Wa
RVA-specific homologous porcine IgG Abs (VHH, IgY and IgG
groups respectively). During the first 24 h of life, piglets received
commercial sterilized bovine milk (RVA Ab free) for human
consumption (Parmalat, St. Paul, USA) ad libitum. From the second
day of life on, the milk diet consisted of 210 ml of RVA Ab free
commercial milk supplemented with the corresponding volume of
passive treatment pools, as described in Table 1, twice a day (9
days of passive treatment). A No Treatment (NT) group of pigs
received no Ab treatment and was fed only the commercial milk.
The passive treatment administration started after the main period
of gut closure, at approximately 36 h of age, in order to reduce
systemic Ab absorption [83,84]. From the end of the passive
treatments onwards, all pigs were fed only the Ab free milk twice a
day until the end of the experiment at 21 post inoculation days
(PID).
Pig virus inoculation, clinical observations and sample
collection. At 72 h of age, pigs in all groups received 5 ml of
100 mM sodium bicarbonate (pH 9.5, to neutralize gastric
acidity), followed by 106.7 FFU of RVA Wa in 5 ml of MEM
(Invitrogen) [64]. The 50% infectious dose (ID50) and diarrhea
dose (DD50) of RVA Wa was determined previously in Gn pigs as
#1 FFU [85,86]. After inoculation, piglets were examined daily
for diarrhea and virus shedding from PID 0 to 21. To estimate the
severity of the diarrhea, fecal consistency was scored a blinded
manner by the same individual throughout as follows: 0: normal;
1: pasty; 2: semi-liquid; 3: liquid. A score equal or greater than 2
was considered diarrhea. Prior and after RVA Wa inoculation,
rectal swabs were collected daily to assess virus shedding. Briefly,
swabs were resuspended in 8 ml MEM (Invitrogen), corresponding
to a 1:25 dilution. All samples were tested by ELISA for assessment
of antigen shedding and by cell culture immunofluorescence
(CCIF) assay for detection of infectious virus shedding. Serum
samples were collected before the beginning of the passive
treatments (within 24 h after birth), at virus inoculation, and then
weekly (PID 7, 14 and 21). Serum Ab levels to Wa RVA were
measured by isotype-specific ELISA and VN assays. The presence
of coproantibodies (coproAb) was also assessed by ELISA. At PID
2163, the animals were euthanized to study the Ab secreting cells
responses to Wa RVA. The primary RVA-specific Ab secreting
cells (ASC) were quantified by ELISPOT assay in the following
gut-associated lymphoid tissues (GALT): duodenum, jejunum and
ileum lamina propria (LP), mesenteric lymph nodes (MLN); and in
the systemic lymphoid tissue spleen and the blood (PBL). Large
(LIC) and small (SIC) intestinal contents from all the piglets were
collected at necropsy for coproAb detection by ELISA [63,64].
RVA antigen and viral detection
Human Wa RVA shedding was detected in rectal swab fluids
using an antigen capture ELISA as described previously
[63,64,87]. Virus infectious titer was assessed by CCIF assay as
described previously [52]. Fluorescent cells were counted using a
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fluorescence microscope and titers were expressed as the number
of fluorescent focus forming units per ml (FFU/ml). The area
under the virus shedding (FFU/ml by CCIF) curve through time
(PID) (AUC) was calculated using statistical software and expressed
as FFU/ml*day. First, the AUC for each piglet was determined
and then the average AUC was calculated for the group.
Wa RVA-specific recombinant VHH nanoAb ELISA
The VHH nanoAb titers to Wa RVA were quantified in the
VP6-specific VHH nanoAb pool, supplemented milk, pig sera,
rectal swab fluids, LIC and SIC. Briefly, 96 well ELISA plates
(Maxisorp, NUNC, Roskilde, Denmark) were coated with
1:10,000 dilution of RVA-specific guinea pig polyclonal serum at
37uC during 1 h and then incubated with 10% nonfat milk in
PBS-Tween 0.05% for blocking of non-specific activity. The
supernatants of semi-purified attenuated (Att) Wa RVA-infected
(105 FFU/ml) MA-104 cell culture lysates or mock infected MA-
104 cell lysates were then added, followed by serial four-fold
dilutions of the samples. VHH were detected using a rabbit
polyclonal anti-VHH serum (1:7,000 dilution). This rabbit
antiserum was made in house, vaccinating the animal with a
cocktail of several VHH nanoAbs. The plates were later incubated
with commercial HRP-labeled goat polyclonal Abs to rabbit IgG
at a 1:2,000 dilution (KPL, Kirkegaard & Perry Laboratories Inc.,
Gaithersburg, USA) at 37uC for 1 h. Hydrogen peroxide and 2,29-
azino-bis(3-ethylbenzothiazoline-6-sulphonic acid (ABTS) were
used as substrate/chromogen system (KPL, Kirkegaard & Perry
Laboratories Inc.). The cut off point for the assay was established
as the mean plus three standard deviations of the optical density
measured in virus-coated PBS wells (blank).
Wa RVA-specific IgY Ab ELISA
The IgY Ab titers to Wa RVA were determined in hen sera,
crude egg yolks, purified IgY pools, supplemented milks, pig sera,
rectal swabs, LIC, and SIC by an indirect ELISA as described
elsewhere [53]. The cut off point for the assay was established as
the mean plus three standard deviations of the optical density
measured in virus-coated PBS wells (blank).
Porcine isotype-specific Ab to Wa RVA ELISA
The IgM, IgA and IgG Ab titers to Wa RVA were quantified in
the Wa RVA porcine IgG Ab pool, pig sera, rectal swab fluids,
LIC, and SIC. Specific Abs to Wa RVA were detected by an
indirect ELISA using the reagents and protocol described
previously [63,64,82]. The cut off point for the assay was
established as mean plus three standard deviations of the optical
density measured in virus-coated PBS wells (blank).
Porcine IgG and IgA Ab ELISA to recombinant VHH
The IgG Ab titers to recombinant VHH were quantified in the
pig sera, rectal swab contents, LIC, and SIC. The IgA Ab titers to
recombinant VHH were quantified only in rectal swab contents,
LIC, and SIC. Briefly, 96 well ELISA plates (Maxisorp, NUNC)
were coated with 1 mg per well of purified bivalent VHH nanoAbs
(provided by Algenex S.L., Madrid, Spain) and then incubated
with 10% nonfat milk in PBS-Tween 0.05% for blocking of non-
specific activity. Serial four-fold dilutions of porcine serum, rectal
swab contents or intestinal content samples were incubated for 1 h
at 37uC. The plates were later incubated with commercial HRP-
labeled goat polyclonal Abs to porcine IgA at 1:3000 dilution
(AbD Serotec Inc., Raleigh, USA) or with commercial biotin-
labeled goat polyclonal Abs to porcine IgG at a 1:20,000 dilution
(KPL, Kirkegaard & Perry Laboratories Inc.) for 1 h at 37uC. The
wells that contained commercial anti-pig IgG Ab were later
incubated with commercial HRP-labeled streptavidin (1:10,000)
(Sigma-Aldrich, Munich, Germany) for 1 h at 37uC. Hydrogen
peroxide and ABTS were used as substrate/chromogen system
(KPL, Kirkegaard & Perry Laboratories Inc.). This ELISA was
also performed using a second set of reagents (HRP-labeled
commercial anti-pig IgG Ab from KPL, Kirkegaard & Perry
Laboratories Inc.) to confirm the results obtained. The cut off
point for the assay was established as the mean plus three standard
deviations of the optical density measured in virus-coated PBS
wells (blank). The ELISA used to detect porcine Abs against VHH
nanoAbs in the present study was analytically validated against
positive control sera from animals systemically immunized with a
pool of VHH nanoAbs. This assay was able to detect the presence
of VHH -specific Abs in this samples that were then considered
positive controls for each assay performed.
Porcine IgG and IgA Ab ELISA to chicken IgY
The IgG Ab titers to chicken IgY were quantified in the pig
sera, LIC, and SIC. The IgA Ab titers to IgY Ab were quantified
only in LIC and SIC. Specific Abs to IgY Ab treatment were
detected by an indirect ELISA using the reagents and protocol
described previously [53]. The ELISA used in the present study to
detect porcine Abs against IgY Ab was analytically validated
against positive control sera from animals systemically immunized
with IgY Abs. This assay was able to detect the presence of IgY-
specific Abs in this samples that were then considered positive
controls for each assay performed.
Fluorescent focus reduction virus neutralization (FFN)
test
The VN Ab titers to Wa RVA in passive treatment pools, egg
yolks, supplemented milks, and pig sera were determined by
fluorescent focus neutralization (FFN) test as previously described
[63]. For in vitro RVA fluorescent focus reduction assay using
different RVA strains, a fourfold dilution of each VHH clone (3B2
or a non-related clone) was mixed with an equal volume of RVA
containing 100 DICT. The VN titer was expressed as the
reciprocal of the highest sample dilution that resulted in .80%
reduction in the number of fluorescent foci. The 80% reduction
criterion was selected in order to be more stringent than in
protocols considering only 50% reduction.
Isolation of mononuclear cells (MNCs) and Wa RVA-
specific ELISPOT assay
Tissue samples of duodenum, jejunum, and ileum lamina
propria were collected. The MLNs were collected and processed
separately. The MNCs from blood and spleen were extracted to
evaluate ASC responses in systemic lymphoid tissues. All the MNC
suspensions were obtained as previously described for pig tissues
and blood [82] and the purified cells from all tissues and blood
were resuspended to a final concentration of 56106 MNC/ml in
RPMI-1640 (GIBCO) supplemented with 10% FBS, 20 mM
HEPES, 2 mM Glutamine, 1 mM sodium pyruvate, 0.1 mM non-
essential amino acids, 100 IU/ml penicillin, 67 mg/ml strepto-
mycin and 50 mg/ml gentamycin (E-RPMI). The cell viability of
each MNC suspension was assessed by Trypan blue exclusion (in
all cases it was .90%). An ELISPOT assay for quantification of
Wa RVA specific IgM, IgA, IgG ASC was conducted to evaluate
effector B-cell responses from all piglets at PID 21, as previously
described [53,63,64,82]. The spots were developed with a
tetramethylbenzidine peroxidase substrate system (TMB, KPL,
Kirkegaard & Perry Laboratories, Inc.).
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Statistical analysis
Fisher’s exact test was used to compare proportions of animals
with diarrhea and virus shedding among groups. The Kruskall-
Wallis rank sum test (non-parametric) was used to compare days of
onset and duration of diarrhea and virus shedding, cumulative
diarrhea scores and cumulative titers of virus shed (area under the
curve, AUC) among groups that were recorded from PID 0 to 21.
Negative samples at a dilution of 1:4 were assigned an arbitrary Ab
titer of 2 for the calculation of geometric mean titers (GMTs).
Neutralizing and isotype-specific Ab titers were log10-transformed
prior to statistical analysis. Differences in Ab titers among groups
were evaluated by comparison of means at four different time-points
post virus inoculation (PID 0, 7, 14, 21). Multiple comparison test of
repeated measures throughout time was done following Akaike
criteria for the selection of covariance matrices [88,89]. In further
comparisons of treatments and post virus inoculation time-points,
Sˇida´k’s correction was applied [90]. At PID 21, the ASC numbers
were compared among groups using the Kruskall-Wallis rank sum
test. Statistical significance was assessed at p,0.05 for all
comparisons. Statistical analyses were conducted using Infostat
statistical software and MedCalc version 11.1.1.0 statistical
software. Statistical analysis is available upon request.
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